The thiazolidinediones: a new class of antidiabetic agents.
Insulin resistance is a fundamental feature of type 2 diabetes and is strongly associated with metabolic disorders which predict increased cardiovascular risk, including hypertension and dyslipidaemia. A new class of insulin-sensitizing agents, the thiazolidinediones, reduce insulin resistance and improve glycaemia both as monotherapy and in combination with sulphonylureas or metformin.
Barnett
A
A
Department of Medicine, Birmingham Heartlands Hospital.
D001786:Blood Glucose / Q000187:drug effects; D003327:Coronary Disease / Q000209:etiology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D018160:Receptors, Cytoplasmic and Nuclear